Table 2.
Laboratory values prior to and 12-months after DFX FCT treatment.
| Variable | Study Entry | Study End | |
|---|---|---|---|
| Median DFX FCT dose (range), mg/kg/d | 14.3 (10–22.5) | 18 (7.5–22.5) | p = 0.011 |
| Median serum ferritin (range), ng/mL | 1143 (345–2253) | 1117 (318–3256) | p = 0.510 |
| Median sCr(range), mg/dL | 0.65 (0.4–0.9) | 0.66 (0.45–0.99) | p = 0.165 |
| Median GFR (range), mL/min | 93 (72–141) | 92 (71–139) | p = 0.188 |
| Spot urinary protein:creatinine ratio | 0.06 | 0.06 | p = 0.547 |
| Spot urinary calcium:creatinine ratio | 0.16 | 0.21 | p = 0.100 |
| AST (range), U/L | 22.5(12–49) | 22 (14–111) | p = 0.173 |
| ALT (range), U/L | 14 (6–31) | 15 U/L (7–127) | p = 0.076 |
| Bilirubin (range), mg/dL | 1.95 (0.61–10.8) | 1.79 (0.91–14.81) | p = 0.089 |
| ALP (range), U/L | 137 (71–506) | 159 (59–445) | p = 0.710 |
| LIC (range), mg/g/dry weight | 4.86 (1.1–12) | 4.01 (1.4–13.75) | p = 0.142 |
| Cardiac MRI T2*, ms | 28.8 (21.5–38.3) | 33.5 (22.3–68.2) | p = 0.006 |
DFX FCT: deferasirox film coated tablet, sCr: serum creatinine, GFR: glomerular filtration rate, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, MRI: magnetic resonance imaging.